|Bid||42.79 x 120700|
|Ask||42.78 x 6100|
|Day's range||42.55 - 43.41|
|52-week range||24.25 - 51.54|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||13.03|
|Earnings date||29 Oct 2020|
|Forward dividend & yield||0.84 (1.99%)|
|Ex-dividend date||31 Aug 2020|
|1y target est||N/A|
Fresenius (FMS) could produce exceptional returns because of its solid growth attributes.
The group said its separately listed dialysis unit, Fresenius Medical Care, showed very strong earnings growth and exceptional cash flow in the quarter. For 2020, Fresenius expects adjusted net income change between a negative 4% and a positive 1%, and revenue growth in the range of 3% to 6%, compared to its previous forecast for growth between 1% to 5% and 4% to 7%, respectively, which did not account for the pandemic's effects. Fresenius' second-quarter net income came in at 410 million euros ($482.6 million), above analysts' average forecast of 398 million euros, according to a company-provided poll.
In its first forecasts factoring in the impact of the pandemic, the company said it expected adjusted net income this year within a range of down 4% to up 1% from last year, and revenue growth of 3-6%. The pandemic has been a mixed blessing for healthcare companies, bringing increased demand for selected products and services but also delays in treatments and extra expenses. While the number of post-acute treatments should gradually recover, postponed site inspections will cut Fresenius' 2020 product launches by about 30% and project delays may last well into the second half, Sturm said.